Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
FIRST EXPERIENCE WITH PROGNOSTIC FACTORS IN UNSELECTED NEUROBLASTOMA PATIENTS - THE AUSTRIAN NEUROBLASTOMA-87 STUDY
Autore:
LADENSTEIN R; URBAN C; GADNER H; FINK FM; ZOUBEK A; EMMINGER W; GRIENBERGER H; SCHMITT K; AMBROS PF; AMBROS IM; HORCHER E; AMANN G; HOFLER G; KERBEL R; MUTZ I;
Indirizzi:
ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,KINDERSPITALGASSE 6 A-1090 VIENNA AUSTRIA GRAZ UNIV,DEPT PAEDIAT ONCOL GRAZ AUSTRIA INNSBRUCK UNIV,DEPT PAEDIAT ONCOL INNSBRUCK AUSTRIA LANDESKRANKENHAUS SALZBURG SALZBURG AUSTRIA UNIV VIENNA,DEPT PAEDIAT SURG VIENNA AUSTRIA UNIV VIENNA,DEPT PATHOL VIENNA AUSTRIA GRAZ UNIV,DEPT PATHOL GRAZ AUSTRIA LANDESKRANKENHAUS LEOBEN LEOBEN AUSTRIA
Titolo Testata:
European journal of cancer
fascicolo: 4, volume: 31A, anno: 1995,
pagine: 637 - 641
SICI:
0959-8049(1995)31A:4<637:FEWPFI>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
II NEURO-BLASTOMA; RADIATION-THERAPY; STAGE; METASTASES; CHILDREN; DISEASE;
Keywords:
NEUROBLASTOMA; PROSPECTIVE STUDY; PROGNOSTIC FACTORS; NEURON SPECIFIC ENOLASE; FERRITIN; AGE; MYCN; DEL 1P;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
R. Ladenstein et al., "FIRST EXPERIENCE WITH PROGNOSTIC FACTORS IN UNSELECTED NEUROBLASTOMA PATIENTS - THE AUSTRIAN NEUROBLASTOMA-87 STUDY", European journal of cancer, 31A(4), 1995, pp. 637-641

Abstract

Between January 1987 and December 1993, 117 patients were registered in the Austrian A-NB87 study. The male/female ratio was 1.18, with 50 patients below the age of 1 year at diagnosis. Patients were assigned to stage according to the result of primary surgery in localised disease. Age, ferritin and neuron specific enolase were used in addition instage III disease for risk-adapted treatment. Adrenal or pelvic primary tumour sites were mainly associated (81%) with advanced disease. The median observation time of the study is 3.5 years. The overall survival at 3 years was excellent in low stage disease and IVs patients, i.e. 100% for stage I and IIA (20 patients), 92% in stage IVs (13 patients), 81% in stage IIIA (18 patients) and 69% in stage IIB (8 patients). Stage IV (38 patients) showed a survival rate of 51%, whereas stage IIIB (10 patients) had the worst outcome in this study, i.e. 20%, due to treatment-related toxicity. Significant unfavourable prognostic factors were neuron specific enolase (NSE)> 100 ng/ml, ferritin > 300 mu g/ml and amplified MYCN. This study achieved a better survival rate instage IV patients and a subgroup of stage III in comparison to our previous study (Padiatrie und Padologie 1986, 21, 269) and gives the basis to further reduce treatment intensity in low-risk disease based on biological factors. However, prognosis for high-risk cases was still poor in spite of a very aggressive treatment concept.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 09:58:46